Browse by Audience
Skip to content
Papers of the Week
Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC.
Abstract
Primary sclerosing cholangitis (PSC) is a major unmet medical need in clinical hepatology. Cilofexor is a non-steroidal FXR agonist being evaluated for the treatment of PSC. Here, we describe the safety and preliminary efficacy of cilofexor in a 96-week, open-label extension (OLE) of a phase 2 trial.